Prostate cancer metastases to bone: Observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features

Archivio Italiano di Urologia e Andrologia

Volumn 80, Issue 2, 2008, Pages 59-64

  Conti, Giario ^a   La Torre, Giuseppe ^b   Cicalese, Virgilio ^c,g   Micheletti, Gennaro ^c,g   Ludovico, Maria Giuseppe ^c,h   Vestita, Giovanni Donato ^c,h   Cottonaro, Giuseppe ^d,i   Introini, Carlo ^e   Cecchi, Massimo ^f  

^a SANT ANNA HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UO Urologia ^*

^d GARIBALDI HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f AUSL 12 di Viareggio   (Italy)

^g S G MOSCATI HOSPITAL   (Italy)

^h Presidio Ospedaliero Monopoli Conversano   (Italy)

ⁱ Ospedale Garibaldi Catania   (United States)

Author keywords

Clinical course; Metastasis to bone; Observational study; Presentation pattern; Prostatic cancer; Protocol; Treatment modes

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE METASTASIS; CANCER LOCALIZATION; CANCER PATIENT; CERVICAL SPINE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; EVALUATION; FEMUR; FOLLOW UP; GLEASON SCORE; HUMAN; ITALY; LUMBAR SPINE; MAJOR CLINICAL STUDY; PATHOLOGIC FRACTURE; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; RIB; SYMPTOMATOLOGY;

EID: 46749109670     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31:578.
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584.
3. Damon NA. Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Curr Opin Urol 2002; 12:413.
4. Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002; 10:399.
5. Paule B, Cicco A. (Biphosphonates in the treatment of bone metastasis of prostatic cancer) Prog Urol 2001; 11:1205.
6. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001; 166:2023.
7. Quaglia A, Vercelli M, Puppo A, Casella C, Artioli E, Crocetti E, Falcini F, Ramazzotti V, Tagliabue G, Prostate Working Group. Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants. Eur J Cancer Prev 2003; 12:145.
8. Bono AV, Rocca Rossetti S, Vercelli M, Marcozzi L REICAP: prospective epidemiologic study of prostate cancer in Italy. Preliminary results. Ricerca Epidemiologica Italiana sul Carcinoma Prostatico. Eur Urol 1996; 30 (Suppl 1):2.
9. Smith MR, Cook R, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007; 70:315.
10. Major P. Optimal management of metastatic bone disease. Eur J Oncol Nurs 2007; 11 Suppl 2:S32.
11. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007; 178:1423.